{
    "clinical_study": {
        "@rank": "124422", 
        "arm_group": [
            {
                "arm_group_label": "BI695500", 
                "arm_group_type": "Experimental", 
                "description": "BI695500, once a week for 4 weeks (4 administrations in total)"
            }, 
            {
                "arm_group_label": "MabThera", 
                "arm_group_type": "Active Comparator", 
                "description": "MabThera, once a week for 4 weeks (4 administration in total)"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of the study is to assess the pharmacokinetic (PK) similarity of\n      Boehringer Ingelheim (BI) 695500 vs. rituximab (MabThera\u00ae) in previously untreated patients\n      with low tumor burden follicular lymphoma (LTBFL).\n\n      The secondary objective of the study is to evaluate the pharmacodynamics (PD), safety, and\n      anti-tumor activity of BI 695500 vs. rituximab (MabThera\u00ae), as well as the presence of\n      anti-drug antibodies (ADAs)."
        }, 
        "brief_title": "Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Lymphoma", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Lymphoma, Follicular", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Follicular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Must give written informed consent and be willing to follow this CTP.\n\n          -  Male or female patients, at least 18 years of age at Screening.\n\n          -  Histologically-confirmed, stage II - IV NHL (CD20+ FL of Grades 1, 2, or 3a).\n\n          -  Low tumor burden according to the GELF criteria - no nodal or extranodal involvement\n             of more than 7 cm, no B symptoms (i.e., fever >38\u00b0C, weight loss - unexplained loss\n             of >10 % body weight over the past 6 months, and sweats - the presence of drenching\n             night sweats), no significant splenomegaly, no pleural effusion, no complications\n             such as ascites or organ compression, and normal serum lactate dehydrogenase (LDH)\n             and \u00df2-microglobulin levels.\n\n          -  Availability of tumor sample within 6 months prior to screening.\n\n          -  Patients not previously treated for their FL.\n\n          -  ECOG performance status of 0 to 1.\n\n          -  Have at least 1 measurable lesion as per the International Working Group (IWG)\n             criteria 2007 at Screening (lesion clearly measurable in at least 2 perpendicular\n             dimensions; see Appendix 10.1 for further details).\n\n          -  Adequate hematological function (unless abnormalities are related to lymphoma\n             infiltration of the bone marrow) within 28 days prior to randomization, including:\n\n          -  - hemoglobin =9.0 g/dL (=5.6 mmol/L).\n\n          -  - absolute neutrophil count =1.5 \u00d7 10^9/L.\n\n          -  - platelet count =100 \u00d7 10^9/L.\n\n          -  Adequate renal and liver function:\n\n          -  - serum creatinine <2.0 mg/dL (<176.8 mcmol/L).\n\n          -  - total bilirubin <2.0 mg/dL (<34 mcmol/L) except for patient with Gilbert's Syndrome\n             or Hemolysis. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <3\n             x upper limit of normal (ULN) (<5 x ULN is acceptable if abnormalities are thought to\n             be related to hepatic infiltration by FL).\n\n          -  For participants of reproductive potential (males and females), use of a medically\n             acceptable method of contraception during the trial, i.e., a combination of 2 forms\n             of effective contraception (defined as hormonal contraception, intrauterine device,\n             condom with spermicide, etc.). Females of childbearing potential must also agree to\n             use an acceptable method of contraception (see above) for 12 months following\n             completion or discontinuation from the trial medication.\n\n        Exclusion criteria:\n\n          -  Transformation to high-grade lymphoma (secondary to low-grade lymphoma).\n\n          -  Presence or history of central nervous system lymphoma.\n\n          -  Patients receiving current treatment with corticosteroids must not be receiving a\n             dose exceeding 20 mg/day prednisone or equivalent.\n\n          -  Patients with prior or concomitant malignancies within 5 years prior to screening\n             except non-melanoma skin cancer, adequately treated carcinoma in situ of the cervix,\n             adequately treated breast cancer in situ, localized prostate cancer stage T1c -\n             provided that the patient underwent curative treatment, and remains relapse free.\n\n          -  Major surgery (excluding lymph node biopsy) within 28 days prior to randomization.\n\n          -  Active, chronic or persistent infection that might worsen with immunosuppressive\n             treatment (e.g., Human Immunodeficiency Virus [HIV], Hepatitis C Virus [HCV], Herpes\n             Zoster).\n\n          -  Patients with chronic active HBV infection. Patients seropositive because of HBV\n             vaccine are eligible. Patients with serologic evidence of past infection may\n             participate if they agree to receive a course of antiviral prophylaxis beginning with\n             the first infusion of BI 695500/rituximab (MabThera\u00ae), and according to local\n             guidelines.\n\n          -  Serious underlying medical conditions, which, per the investigator\u00bfs discretion,\n             could impair the ability of the patient to participate in the trial (including but\n             not limited to ongoing severe infection, severe immunosuppression, severe heart\n             failure, uncontrolled hypertension, uncontrolled diabetes mellitus, gastric ulcers,\n             active autoimmune disease).\n\n          -  Known hypersensitivity or allergy to murine products.\n\n          -  History of a severe allergic reaction or anaphylactic reaction to a biological agent\n             or history of hypersensitivity to any component of the trial drug.\n\n          -  Receipt of a live/attenuated vaccine within 12 weeks prior to the Screening Visit.\n\n          -  Prior treatment with BI 695500 and/or rituximab.\n\n          -  Patients who received any prior therapy using monoclonal antibodies will be excluded;\n             this does not apply to other biological drugs such as growth factors or\n             anticoagulants.\n\n          -  Treatment within a clinical trial within 4 weeks prior to initiation of trial\n             treatment. Patients who have received treatment with a drug that has not received\n             regulatory approval for any indication within 4 weeks or a minimum of 5 half-lives,\n             whichever is longer, of the initial dose of trial medication.\n\n          -  Any other co-existing medical or psychological condition(s) that will preclude\n             participation in the trial or compromise ability to give informed consent and/or\n             comply with study procedures.\n\n          -  Pregnancy or breast feeding. For women of childbearing potential, a positive serum\n             pregnancy test at the Screening Visit.\n\n          -  Patients who have significant cardiac disease, including but not limited to\n             congestive heart failure of Class III or IV of the New York Heart Association (NYHA)\n             classification; uncontrolled angina or arrhythmia; any uncontrolled or severe\n             cardiovascular or cerebrovascular disease; or uncontrolled hypertension.\n\n          -  Positive HIV or tuberculosis (TB) at screening (screening for HIV and TB to be\n             performed according to local practice and local regulatory guidance)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01950273", 
            "org_study_id": "1301.5", 
            "secondary_id": "2013-001904-12"
        }, 
        "intervention": [
            {
                "arm_group_label": "BI695500", 
                "description": "BI695500, once a week for 4 weeks (4 administrations in total)", 
                "intervention_name": "BI 695500", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MabThera", 
                "description": "MabThera, once a week for 4 weeks (4 administrations in total)", 
                "intervention_name": "MabThera", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Rituximab"
        }, 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Canberra", 
                        "country": "Australia"
                    }, 
                    "name": "1301.5.0218 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bruxelles", 
                        "country": "Belgium"
                    }, 
                    "name": "1301.5.0306 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edegem", 
                        "country": "Belgium"
                    }, 
                    "name": "1301.5.0304 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Namur", 
                        "country": "Belgium"
                    }, 
                    "name": "1301.5.0302 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brno", 
                        "country": "Czech Republic"
                    }, 
                    "name": "1301.5.1104 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ostrava-Poruba", 
                        "country": "Czech Republic"
                    }, 
                    "name": "1301.5.1102 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux cedex", 
                        "country": "France"
                    }, 
                    "name": "1301.5.1508 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brest", 
                        "country": "France"
                    }, 
                    "name": "1301.5.1510 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "La Roche sur Yon", 
                        "country": "France"
                    }, 
                    "name": "1301.5.1506 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pessac", 
                        "country": "France"
                    }, 
                    "name": "1301.5.1504 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Poitiers", 
                        "country": "France"
                    }, 
                    "name": "1301.5.1502 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bad Nauheim", 
                        "country": "Germany"
                    }, 
                    "name": "1301.5.1704 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany"
                    }, 
                    "name": "1301.5.1734 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Goslar", 
                        "country": "Germany"
                    }, 
                    "name": "1301.5.1712 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Germany"
                    }, 
                    "name": "1301.5.1710 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece"
                    }, 
                    "name": "1301.5.1804 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary"
                    }, 
                    "name": "1301.5.2102 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Auckland", 
                        "country": "New Zealand"
                    }, 
                    "name": "1301.5.3402 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bratislava", 
                        "country": "Slovakia"
                    }, 
                    "name": "1301.5.4602 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Badalona", 
                        "country": "Spain"
                    }, 
                    "name": "1301.5.4814 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "C\u00e1diz", 
                        "country": "Spain"
                    }, 
                    "name": "1301.5.4808 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain"
                    }, 
                    "name": "1301.5.4810 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vitoria", 
                        "country": "Spain"
                    }, 
                    "name": "1301.5.4816 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "Belgium", 
                "Czech Republic", 
                "France", 
                "Germany", 
                "Greece", 
                "Hungary", 
                "New Zealand", 
                "Slovakia", 
                "Spain"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Parallel-arm, Phase I Study to Evaluate the Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab (MabThera) Induction Immunotherapy as a First-line Treatment in Patients With Low Tumor Burden Follicular Lymphoma", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Australia: Therapeutic Goods Administration", 
                "Austria: Agency for Health and Food Safety", 
                "Belgium: Federal Agency for Medicinal and Health Products", 
                "Croatia: Ministry of Health of the Republic of Croatia", 
                "Czech Republic: State Institute for Drug Control", 
                "Denmark: The Danish Health and Medicines Authority", 
                "France: Agence Nationale s\u00e9curit\u00e9 m\u00e9dicament et des produits sant\u00e9", 
                "Germany: Paul-Ehrlich-Institut", 
                "Greece: National Organization of Medicines", 
                "Hungary: National Institute of Pharmacy", 
                "Italy: The Italian Medicines Agency", 
                "New Zealand: Medsafe", 
                "Poland: Registration Medicinal Product Medical Device Biocidal Product", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Slovakia: State Institute for Drug Control", 
                "Slovenia: Agency for Medicinal Products and Medical Devices", 
                "Spain: Spanish Agency of Medicines and Medical Devices", 
                "Sweden: Medical Products Agency", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ]
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Area under the curve (AUC) for BI 695500 and rituximab concentrations", 
            "safety_issue": "No", 
            "time_frame": "142 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01950273"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Comparision of AEs between the two study arms", 
                "safety_issue": "No", 
                "time_frame": "142 days"
            }, 
            {
                "measure": "AUC for BI 695500 and rituximab concentrations", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "measure": "Maximum observed concentration of the BI 695500 and rituximab", 
                "safety_issue": "No", 
                "time_frame": "142 days"
            }, 
            {
                "measure": "AUC 0-7 days (area under the depletion-time curve) of the CD19+ B-cells depletion (change from baseline)", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "measure": "Change from baseline of CD19+ B-cells", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "measure": "Tumor response evaluation based on revised International Working Group (IWG) criteria 2007", 
                "safety_issue": "No", 
                "time_frame": "50 days"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}